Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEXO.L Regulatory News (EXO)

  • There is currently no data for EXO

Trading Update

19 Nov 2014 07:00

RNS Number : 3849X
Exova Group PLC
19 November 2014
Β 

ο»Ώ

19 November 2014

Β 

Exova Group plc

Β 

Trading Update

Β 

Exova Group plc (''Exova'' or the ''Group''), a leading international provider of technically demanding testing services, today releases its Trading Update for the period from 1 July 2014 to date. The financial results correspond to the ten month period from 1 January 2014 to 31 October 2014 compared with the corresponding period in 2013.

Β 

Β 

Highlights

Β 

Β· Underlying organic revenue1 growth at constant currency of 3.8% in line with expectations

Β· Total revenue growth on a constant currency basis of 4.0%

Β· Three bolt-on acquisitions and one disposal completed

Β· The Board expects full year underlying organic revenue growth at constant currency to be broadly in line with the year to date

Β 

Β 

Ian El-Mokadem, Chief Executive Officer of Exova, commented:

Β 

"Trading in the last four months has been consistent with our expectations at the time of the half year results. We have also continued to execute our acquisition strategy with the most recent addition of the Metallurgical Services business in India.

Β 

"The medium term outlook for the Group remains positive and we continue to see opportunities to complement organic growth by extending the global reach of our business through new acquisitions and outsourcing agreements."

Β 

Β 

Revenue growth for the ten months to 31 October 2014

Β 

Growth (%)

Constant currency

Underlying organic 1

3.8

Underlying adjustments

(4.2)

Organic 2

(0.4)

Acquisitions

4.9

Disposals

(0.5)

Total

4.0

Currency effect

(6.7)

Reported

(2.7)

Β 

Β 

Β 

Β 

Trading in the period from 1 July 2014 to date

Β 

In Europe, the Health Sciences and Product clusters continued to report good underlying revenue growth including the benefit of contract wins in Health Sciences. In addition, Oil & Gas and Industrials continued to see a strong requirement for technically demanding services offset by some softness in more routine testing. In the Aerospace cluster, although certain client delays and subdued demand affected performance in the first half of the year, we have subsequently seen a modest improvement.

Β 

In the Americas, Oil & Gas and Industrials continued to show strong overall growth with technically demanding testing being particularly robust. Health Sciences also delivered overall growth. Progress in these clusters was largely offset by a general weakness in demand for certain types of testing for the Transportation sector and by weak demand and client specific delays in some Aerospace laboratories.

Β 

In the Rest of World, growth moderated as anticipated in the Middle East cluster after a particularly strong first half of the year. Growth accelerated considerably in the Product cluster as we continued to see the on-going benefits of the investment we made in our Fire Testing business in Australia and strong demand for Fire Consulting services across the region.

Β 

Β 

Acquisitions and disposals

Β 

In addition to the acquisition of Catalyst Environmental in the UK in January 2014 and the calibration business of Raufoss Offshore in Norway in May 2014, the Group completed the acquisition of Metallurgical Services, a leading Oil & Gas and Industrials testing business in India, in July 2014.

Β 

Following a strategic review of our small routine geological core testing and analysis business in Calgary, Canada, the business was sold on 7 November 2014.

Β 

Β 

Outlook

Β 

The Board expects full year underlying organic revenue growth at constant currency to be broadly in line with the year to date.

Β 

Β 

Full year results

Β 

The Group's full year results to 31 December 2014 will be announced on 4 March 2015.

Β 

Β 

Notes:

Β 

1) Underlying organic revenue is organic revenue adjusted for certain non-recurring items associated with a US transportation client within the Product cluster and for the discontinuation of certain food advisory services in the Health Sciences cluster in Europe.

2) Organic revenue growth at constant currency represents revenue growth at constant currency for each year excluding the growth attributable to acquisitions until the acquisition has been owned for a 12 month period and excluding the revenue attributable to disposals in the year of disposal and the preceding year, all at constant currency.

Β 

Β 

Β 

Conference Call

Β 

A conference call to discuss the Trading Update will be held on Wednesday 19 November at 9.00am (UK). Dial-in details are:

Β 

UK:

0844 800 3850

International:

+44 (0) 844 800 3850

Some locations may be unable to access the primary dial-in number. If you are calling from one of these locations, please use +44 (0) 208 996 3900

Β 

Passcode:

261 862

Β 

Β 

Enquiries

Β 

For investors, Exova Group plc

Ian Power, Investor Relations

+44 (0) 131 476 7612

For media, Powerscourt

Ian Middleton / Paul Durman

+44 (0) 20 7250 1446

Β 

Β 

About Exova

Β 

Exova is one of the world's largest dedicated testing groups, trusted by organisations to test and advise on the safety, quality and performance of their products and operations. Headquartered in Edinburgh, UK, Exova operates 118 permanent facilities in 23 countries and employs around 3,800 people throughout Europe, the Americas, the Middle East and Asia/Asia Pacific.

Β 

Exova's capabilities help to extend asset life, bring predictability to applications, and shorten the time to market for customers' products, processes and materials. With over 90 years' experience, Exova specialises in testing across a number of key sectors from food and pharmaceuticals to aerospace, transportation, oil and gas, fire, engineering and construction.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTEAPFPFEFLFFF
Date   Source Headline
24th May 20173:11 pmRNSDirector/PDMR Shareholding
24th May 20171:40 pmRNSResult of AGM
24th May 20171:32 pmRNSAGM Statement
24th May 201712:34 pmRNSForm 8.5 (EPT/RI) - Amendment
24th May 201712:02 pmRNSForm 8.5 (EPT/NON-RI) - Exova Group Plc
24th May 201712:00 pmRNSForm 8.5 (EPT/RI) - Exova Group Plc
24th May 201711:08 amRNSForm 8.3 - Exova Group PLC
24th May 201710:57 amRNSDirector Declaration
24th May 201710:32 amRNSForm 8.5 (EPT/RI)
24th May 201710:13 amRNSForm 8.5 (EPT/RI)
24th May 20179:45 amRNSForm 8.3 - EXOVA GROUP PLC
24th May 20177:00 amRNSTrading Statement
23rd May 201712:20 pmRNSForm 8.5 (EPT/RI) - Exova Group Plc
23rd May 201711:57 amRNSForm 8.3 - Exova Group Plc
23rd May 201710:35 amRNSForm 8.5 (EPT/RI)
22nd May 20173:30 pmRNSForm 8.3 - EXO LN
22nd May 20173:18 pmRNSForm 8.3 - Exova Group Plc
22nd May 201711:52 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
22nd May 201710:34 amRNSForm 8.5 (EPT/RI)
19th May 20172:53 pmBUSForm 8.3 - Exova Group Plc
19th May 20172:03 pmRNSForm 8.3 - [Exova Group Plc]
19th May 20171:57 pmRNSForm 8.3 - Exova Group Plc
19th May 20171:11 pmRNSForm 8.5 (EPT/RI)
19th May 20171:03 pmRNSForm 8.3 - EXOVA GROUP PLC
19th May 201711:35 amRNSForm 8.5 (EPT/RI) Exova Group Plc
19th May 201711:26 amRNSForm 8.5 (EPT/RI)
18th May 201712:22 pmRNSForm 8.3 - Exova Group Plc
18th May 201711:53 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
18th May 201711:52 amRNSForm 8.5 (EPT/NON-RI) - Exova Group Plc
18th May 201711:19 amRNSForm 8.5 (EPT/RI)
18th May 201711:12 amRNSForm 8.3 - Exova Group PLC
18th May 201710:50 amRNSForm 8.5 (EPT/RI)
18th May 20178:30 amRNSAcquisition
17th May 20174:52 pmRNSForm 8.5 (EPT/RI) - Amendment
17th May 20172:56 pmRNSForm 8.3 - Exova Group Plc
17th May 20172:25 pmBUSForm 8.3 - Exova Group Plc
16th May 20172:54 pmBUSForm 8.3 - Exova Group Plc
16th May 201711:52 amRNSForm 8.5 (EPT/RI)
16th May 201711:49 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
16th May 201710:26 amRNSForm 8.3 - EXOVA GROUP PLC
16th May 201710:25 amRNSForm 8.5 (EPT/RI)
15th May 20173:30 pmRNSForm 8.3 - EXO LN
15th May 201711:54 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
15th May 201711:44 amRNSForm 8.3 - Exova Group PLC
15th May 201711:13 amRNSForm 8.5 (EPT/RI)
15th May 201710:41 amRNSForm 8.5 (EPT/RI)
15th May 20179:44 amRNSForm 8.3 - EXOVA GROUP PLC
15th May 20179:39 amRNSDeadline for clarification by Jacobs and PAI
12th May 20173:43 pmRNSRECOMMENDED ACQUISITION OF EXOVA REGULATORY UPDATE
12th May 201711:29 amRNSForm 8.5 (EPT/RI) - Exova Group Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.